Clinical Trials Logo

Filter by:
NCT ID: NCT03529032 Completed - Pain, Postoperative Clinical Trials

Preoperative Methadone Single Dose Reduces Postoperative Morphine Consumption.

Start date: March 2012
Phase: Phase 4
Study type: Interventional

The aim of this study was to evaluate the effect of intraoperative methadone on postoperative analgesic requirements, pain scores and patient satisfaction in comparison to standard intraoperative pain control with fentanyl in laparoscopic surgery.

NCT ID: NCT03528096 Completed - Clinical trials for Sleep Related Rhythmic Movement Disorder (Disorder)

Vestibular Stimulation Therapy for Rhythmic Movement Disorder

Start date: March 30, 2018
Phase: N/A
Study type: Interventional

This study aims to a) investigate the feasibility of the detection of episodes of RMD using contactless 3D video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.

NCT ID: NCT03527576 Recruiting - Postoperative Pain Clinical Trials

Block Duration After Spinal Block and iv Dexamethasone.

Start date: May 1, 2018
Phase: Phase 4
Study type: Interventional

It has been largely demonstrated that iv dexamethasone prolongs the duration of analgesia after peripheral nerve block. However, data are missing regarding the duration of analgesia after spinal block. The objective of this randomized controlled double-blinded trial is to assess whether intravenous dexamethasone administered after a spinal block, before the surgery would prolong sensory block characteristics without impacting the motor block duration.

NCT ID: NCT03527407 Recruiting - Hip Injuries Clinical Trials

MIDAS: Minimal-dataset for the Assessment of Surgical Outcomes - Potential in Hip Surgery

Start date: July 1, 2017
Phase:
Study type: Observational

Swiss legislation requires health service providers to collect such information. of medical quality indicators as part of the quality and performance audit (Article 22a KVG). In addition, comparisons of clinics or specialist specialists on cost and quality of results are required (Art. 49 (8)). Currently, the quality of a medical therapy is evaluated rather negatively on the absence (or occurrence) of complications. In contrast, however, the goal of therapy must be to improve or maintain the health-related quality of life (HRQoL). Accordingly, the Swiss Society of Surgery (SGC-SSC), in collaboration with the Association for Quality Assurance in Surgery (AQC), has developed a minimum dataset designed to assess the quality of life of patients after surgical intervention. In order to enable Switzerland to be comparatively independent of the discipline, generic (in the Research Plan - MIDAS -V2, date 24.05.2017 Page 5/57 Contrary to disease-specific) survey instruments proposed that cover the general quality of life in its different facets, regardless of the function of individual organ systems. The complication documentation was not completely abandoned in this proposal, but is only a quality indicator among many due to patient-related outcome measurements. However, the development of a minimal data set with quality indicators that are applicable across all surgical sub-disciplines for evaluating the quality of treatment of acute and chronic diseases raises a number of fundamental questions that can only be answered to a limited extent without empirical studies. Five essential questions are: I. Is it sufficient to work with generic quality of life tools or is it necessary to use disease / indication specific instruments or functional tests? II. Which is the best, solid time for a follow-up? III. Is it possible and useful to make a third-party determination of the quality of life in patients with limited cognitive abilities? IV. Which preoperative risk factors should be documented so that sufficient adjustment for case mix differences in hospital comparisons can be made? V. Which perioperative and postoperative factors, in particular complications, must be raised beyond the quality of life, as they reflect an independent aspect of quality?

NCT ID: NCT03527316 Not yet recruiting - Healthy Clinical Trials

Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction

MFE
Start date: August 2018
Phase: Early Phase 1
Study type: Interventional

Serotonin and oxytocin play a role in fear conditioning and fear extinction learning, psychological processes that are critically involved in psychiatric disorders such as posttraumatic stress disorder (PTSD). Specifically, administration of oxytocin has been shown to facilitate fear extinction in humans. Similarly, substances that release serotonin and oxytocin such as MDMA have been shown to enhance the extinction of fear memory in animals. However, there are no data on the effects of MDMA on fear extinction in humans. Therefore, the primary aim of this study is to investigate the role of acute serotonin release in the effects of fear extinction. MDMA will be used as pharmacological tool to induce serotonin release in this study.

NCT ID: NCT03527030 Recruiting - Tobacco Use Clinical Trials

Cross-Sectional Survey on the Use of Tobacco Products - London (UK)

Start date: March 5, 2018
Phase:
Study type: Observational

The main purpose of the research study is to estimate the prevalence of tobacco product use and describe the tobacco use patterns in adults in London, United Kingdom.

NCT ID: NCT03527017 Recruiting - Tobacco Use Clinical Trials

Cross-Sectional Survey on the Use of Tobacco Products - Germany

Start date: March 12, 2018
Phase:
Study type: Observational

The main purpose of the research study is to estimate the prevalence of tobacco product use and describe the tobacco use patterns in adults in Germany.

NCT ID: NCT03527004 Recruiting - Tobacco Use Clinical Trials

Cross-Sectional Survey on the Use of Tobacco Products - Italy

Start date: March 20, 2018
Phase:
Study type: Observational

The main purpose of the research study is to estimate the prevalence of tobacco product use and describe the tobacco use patterns in adults in Italy.

NCT ID: NCT03526029 Recruiting - Trauma Clinical Trials

Swiss Trauma Registry

ch18Jakob2
Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

The Swiss Conference of Cantonal Health Directors has transferred the planning of highly specialized medicine to a specialized body under the direction of the Swiss Academy of Sciences. This specialist body has defined the treatment of critically ill as part of highly specialized medicine and founded the Swiss Trauma Registry at 12 hospitals in Switzerland. The registry is designed to provide a consistent and standardized approach and treatment outcomes in the short and long term quality control and as a basis for planning highly specialized medicine.

NCT ID: NCT03524898 Not yet recruiting - Soft Tissue Sarcoma Clinical Trials

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Start date: August 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial with biweekly regimen of gemcitabine and nab-paclitaxel for Soft tissue sarcomas (STSs). A Promising antitumor activity in patients with metastatic STS has been reported with gemcitabine alone or in combination with taxanes including docetaxel and paclitaxel in pre-treated patients. Nab-paclitaxel is a 130-nm albumin-bound formulation of paclitaxel particles (Celgene, Summit, NJ) which was designed to eliminate the toxicities associated with Cremophor®-EL. Nab-paclitaxel at equal dose of paclitaxel showed increased antitumor activity, enhanced endothelial cell transport and 33% higher intra-tumor paclitaxel concentration in preclinical models of solid tumor xenografts promising an advantageous pharmacokinetic profile In sarcoma, nab-paclitaxel demonstrated preclinical anti-tumor activity in rhabdomyosarcoma xenograft model. Local relapsed tumors following paclitaxel treatment proved to be paclitaxel-resistant but remained responsive to nab-paclitaxel. These findings provide the rationale for further evaluation of nab-paclitaxel in combination with gemcitabine for soft tissue sarcoma treatment.